Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4688056 | 1.00 | STAT3 (0.74) | STAT3LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL4688054 | 1.00 | STAT3 (0.74) | STAT3LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL1399074 | 0.91 | STAT3 (0.62) | STAT3LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL1399073 | 0.91 | STAT3 (0.62) | STAT3LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL1177984 | 0.89 | STAT3 (0.60) | STAT3LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL6986690 | 0.89 | STAT3 (0.60) | STAT3LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL16466488 | 0.85 | RAB9A (0.56) | STAT3LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL10670403 | 0.85 | BACE1 (0.64) | STAT3LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL10348541 | 0.85 | BACE1 (0.64) | STAT3LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL11155032 | 0.85 | ALDH1A1 (0.62) | STAT3LMNAALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044073-B2 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | TIBOTEC PHARMACEUTICALS (IE) | 2011-10-25 | — | — | US | disclosed |
| US-20070099924-A1 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | JANSSEN SCIENCES IRELAND UC (IE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099924-A1 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-2, H1-4 | STAT3 1131/4885LMNA 1566/4885ALDH1A1 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.